BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives Buy Rating and $70 Target Price; Releases Q1 2023 and Business Update
Analysts at Aegis Capital Corp. continue to recommend shares of the company with a Buy rating and a $70 target price Data from pre-clinical trial indicate that BiondVax’s NanoAb may effectively serve as both a therapeutic and protective prophylactic drug, further enhancing its value proposition BVXV reiterated further NanoAb development beginning with NanoAbs targeting immune system cytokines such as IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis BiondVax aims to optimize the use of assets and generate additional revenues by offering its drug development services and cGMP manufacturing capabilities to others BiondVax Pharmaceuticals (NASDAQ: BVXV),…